ClinicalTrials.gg
CompletedNCT05348356Updated Aug 25, 2026Results posted

Nirogacestat in Ovarian Granulosa Cell Tumors

A Phase 2 interventional study of Nirogacestat in Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor and Ovarian Cancer, sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany. Completed at 21 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Ovarian Neoplasms by Merck KGaA, Darmstadt, Germany — 1 open to participants now, 3 under way, 1 of them phase 3. Ovarian Neoplasms · Merck KGaA, Darmstadt, Germany.

Enrollment
7th of 12
53 · median 57
Started
2022
the only one that year
Phase 2
5 of 12
none open now
Registered
9th of 12
by date

Among the 12 studies in Ovarian Neoplasms by Merck KGaA, Darmstadt, Germany, this one is the 7th largest by enrollment, is the only one that started in 2022, is one of 5 in phase 2, and was the 9th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

1 of the 12 studies in Ovarian Neoplasms by Merck KGaA, Darmstadt, Germany is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Ovarian Neoplasms by Merck KGaA, Darmstadt, Germany, or all of them as a file.
02

Study summary

This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs). Nirogacestat is a gamma secretase inhibitor (GSI) which is hypothesized to decrease the growth and activity of ovarian granulosa tumors.

Read the detailed description

Ovarian granulosa cell tumors (OvGCTs) represent 5-7% of all ovarian cancers (\~1.5 to 2k newly diagnosed patients/year in the United States) and are the most common subtype of ovarian sex cord tumors (70%). Treatment of granulosa cell tumors with nirogacestat is expected to inhibit Notch-induced granulosa cell proliferation.

This is a multi-center, single-arm, Phase 2 open label treatment study to determine the efficacy, safety, tolerability, and pharmacokinetics of nirogacestat in adult participants with relapsed/refractory OvGCT. The participants will continue treatment until disease progression as determined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (unless the participants meet criteria for continued treatment) or unacceptable toxicity.

03

Conditions studied

  • Ovarian Granulosa-Stromal Tumor
  • Ovarian Granulosa Cell Tumor
  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Has confirmed recurrent adult-type granulosa cell tumor of the ovary prior to first dose of study treatment
  • Have documented radiological evidence of relapse after at least one systemic therapy that is not amenable to surgery, or radiation and have by v1.1 criteria
  • Have adequate bone marrow, renal and hepatic function as defined by screening visit laboratory values

Key Exclusion Criteria:

  • Has signs of bowel obstruction requiring parenteral nutrition, malabsorption syndrome or preexisting gastrointestinal conditions that may impair absorption of nirogacestat
  • Has had a major cardiac or thrombo-embolic event within 6 months of signing
  • Has abnormal at Screening, or has congenital or acquired long QT syndrome or a history of additional risk factors for Torsades de Pointes
  • Has current or chronic history of liver disease or known hepatic or biliary abnormalities
  • Has received bevacizumab treatment or other monoclonal antibody therapy with targeted anti-angiogenic activity for OvGCT within 28 days (or 5 half-lives, whichever is shorter) prior to the first dose of study treatment;
  • Has received treatment for OvGCT including but not limited to the following within 28 days (or 5 half-lives, whichever is longer) prior to the first dose of study treatment: hormonal therapy, chemotherapy, immunotherapy, targeted therapy or any treatment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Nirogacestat Open-Label

    Nirogacestat 150 mg by mouth, twice daily Nirogacestat oral tablet: Nirogacestat tablet

    Drug: Nirogacestat

Interventions

  • nirogacestat oral tablet

    Also known as: PF-03084014

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    The percentage of participants with complete response (CR) + partial response (PR) assessed using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.

    Time frame: 2.5 years

Secondary outcomes

  1. Progression Free Survival at 6 Months (PFS-6)

    The number of participants without progression according to RECIST v1.1 or death at 6 months.

    Time frame: First day of cycle 7 (approximately 6 months after the first dose of study treatment). Each cycle is 28 days.

  2. Overall Survival at Year 2

    The number of participants who have not died of any cause by Year 2.

    Time frame: 2 years after first dose of study treatment

  3. Duration of Response

    The time from response (Complete Response \[CR\] + Partial Response \[PR\] using RECIST v.1.) to disease progression and/or death, in participants with CR or PR.

    Time frame: First day of every other cycle (each cycle is 28 days) for the first year, and then every 3 cycles thereafter until study completion (estimated to be an average of 2.5 years).

  4. Change From Baseline at Cycle 2 Day 1 in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score.

    Participant reported ovarian cancer symptoms as measured by Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI). The FOSI is an 8-question evaluation scored on a Likert scale of 0-4 from not at all to very much. Metrics assessed include lack of energy, vomiting, pain, nausea, swelling in stomach area, concern condition will get worse, quality of life assessment and stomach cramps. Higher score means worse outcome. The responses to the statements except for statement 7 (I am content with the quality of my life right now) were reversed and the sum of non-missing responses is calculated. The FOSI score is the sum multiplied by 8, then divided by the number of responded statements. The FOSI score was missing if a participants had 5 or more missing values in the 8 individual symptom scores at a visit.

    Time frame: Baseline and at Cycle 2 Day 1 (cycle length is 28 days).

  5. Change From Baseline at Cycle 3 Day 1 Treatment in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score

    Participant reported ovarian cancer symptoms as measured by Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI). The FOSI is an 8-question evaluation scored on a Likert scale of 0-4 from not at all to very much. Metrics assessed include lack of energy, vomiting, pain, nausea, swelling in stomach area, concern condition will get worse, quality of life assessment and stomach cramps. Higher score means worse outcome. The responses to the statements except for statement 7 (I am content with the quality of my life right now) were reversed and the sum of non-missing responses is calculated. The FOSI score is the sum multiplied by 8, then divided by the number of responded statements. The FOSI score was missing if a participants had 5 or more missing values in the 8 individual symptom scores at a visit.

    Time frame: Baseline and at Cycle 3 Day 1 (cycle length is 28 days).

  6. Change From Baseline at Cycle 4 Day 1 in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score

    Participant reported ovarian cancer symptoms as measured by Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI). The FOSI is an 8-question evaluation scored on a Likert scale of 0-4 from not at all to very much. Metrics assessed include lack of energy, vomiting, pain, nausea, swelling in stomach area, concern condition will get worse, quality of life assessment and stomach cramps. Higher score means worse outcome. The responses to the statements except for statement 7 (I am content with the quality of my life right now) were reversed and the sum of non-missing responses is calculated. The FOSI score is the sum multiplied by 8, then divided by the number of responded statements. The FOSI score was missing if a participants had 5 or more missing values in the 8 individual symptom scores at a visit.

    Time frame: Baseline and at Cycle 4 Day 1 (cycle length is 28 days).

  7. Change From Baseline at Cycle 5 Day 1 in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score

    Participant reported ovarian cancer symptoms as measured by Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI). The FOSI is an 8-question evaluation scored on a Likert scale of 0-4 from not at all to very much. Metrics assessed include lack of energy, vomiting, pain, nausea, swelling in stomach area, concern condition will get worse, quality of life assessment and stomach cramps. Higher score means worse outcome. The responses to the statements except for statement 7 (I am content with the quality of my life right now) were reversed and the sum of non-missing responses is calculated. The FOSI score is the sum multiplied by 8, then divided by the number of responded statements. The FOSI score was missing if a participants had 5 or more missing values in the 8 individual symptom scores at a visit.

    Time frame: Baseline and at Cycle 5 Day 1 (cycle length is 28 days).

  8. Change From Baseline at End of Treatment in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score

    Participant reported ovarian cancer symptoms as measured by Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI). The FOSI is an 8-question evaluation scored on a Likert scale of 0-4 from not at all to very much. Metrics assessed include lack of energy, vomiting, pain, nausea, swelling in stomach area, concern condition will get worse, quality of life assessment and stomach cramps. Higher score means worse outcome. The responses to the statements except for statement 7 (I am content with the quality of my life right now) were reversed and the sum of non-missing responses is calculated. The FOSI score is the sum multiplied by 8, then divided by the number of responded statements. The FOSI score was missing if a participants had 5 or more missing values in the 8 individual symptom scores at a visit.

    Time frame: Baseline and at end of treatment (estimated to be an average of 5.5 months [minimum of 0 month and maximum of 33 months]).

  9. Change From Baseline at Safety Follow-up in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score

    Participant reported ovarian cancer symptoms as measured by Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI). The FOSI is an 8-question evaluation scored on a Likert scale of 0-4 from not at all to very much. Metrics assessed include lack of energy, vomiting, pain, nausea, swelling in stomach area, concern condition will get worse, quality of life assessment and stomach cramps. Higher score means worse outcome. The responses to the statements except for statement 7 (I am content with the quality of my life right now) were reversed and the sum of non-missing responses is calculated. The FOSI score is the sum multiplied by 8, then divided by the number of responded statements. The FOSI score was missing if a participants had 5 or more missing values in the 8 individual symptom scores at a visit.

    Time frame: Baseline and at safety follow-up (up to a maximum of 34 months).

07

Results

Posted Aug 25, 2026

Participant flow

Participant flow — Overall Study
MilestoneNirogacestat Open-Label
Started53
Completed1
Not completed52
Withdrew: Death1
Withdrew: Lack of efficacy38
Withdrew: Withdrawal by subject4
Withdrew: Physician decision8
Withdrew: Clinical progression1

Outcome measures

PrimaryObjective Response Rate (ORR)

The percentage of participants with complete response (CR) + partial response (PR) assessed using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.

Time frame:
2.5 years
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsNirogacestat Open-Label
Objective Response Rate (ORR)0
SecondaryProgression Free Survival at 6 Months (PFS-6)

The number of participants without progression according to RECIST v1.1 or death at 6 months.

Time frame:
First day of cycle 7 (approximately 6 months after the first dose of study treatment). Each cycle is 28 days.
Reported as:
Count of participants · Participants
Progression Free Survival at 6 Months (PFS-6)
ParticipantsNirogacestat Open-Label
Progression Free Survival at 6 Months (PFS-6)22
SecondaryOverall Survival at Year 2

The number of participants who have not died of any cause by Year 2.

Time frame:
2 years after first dose of study treatment
Reported as:
Count of participants · Participants
Overall Survival at Year 2
ParticipantsNirogacestat Open-Label
Overall Survival at Year 247
SecondaryDuration of Response

The time from response (Complete Response \[CR\] + Partial Response \[PR\] using RECIST v.1.) to disease progression and/or death, in participants with CR or PR.

Time frame:
First day of every other cycle (each cycle is 28 days) for the first year, and then every 3 cycles thereafter until study completion (estimated to be an average of 2.5 years).

No measurements were reported for this outcome.

SecondaryChange From Baseline at Cycle 2 Day 1 in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score.

Participant reported ovarian cancer symptoms as measured by Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI). The FOSI is an 8-question evaluation scored on a Likert scale of 0-4 from not at all to very much. Metrics assessed include lack of energy, vomiting, pain, nausea, swelling in stomach area, concern condition will get worse, quality of life assessment and stomach cramps. Higher score means worse outcome. The responses to the statements except for statement 7 (I am content with the quality of my life right now) were reversed and the sum of non-missing responses is calculated. The FOSI score is the sum multiplied by 8, then divided by the number of responded statements. The FOSI score was missing if a participants had 5 or more missing values in the 8 individual symptom scores at a visit.

Time frame:
Baseline and at Cycle 2 Day 1 (cycle length is 28 days).
Reported as:
Mean · score on a scale
Change From Baseline at Cycle 2 Day 1 in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score.
score on a scaleNirogacestat Open-Label
Change From Baseline at Cycle 2 Day 1 in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score.-1.1 ± 3.86
SecondaryChange From Baseline at Cycle 3 Day 1 Treatment in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score

Participant reported ovarian cancer symptoms as measured by Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI). The FOSI is an 8-question evaluation scored on a Likert scale of 0-4 from not at all to very much. Metrics assessed include lack of energy, vomiting, pain, nausea, swelling in stomach area, concern condition will get worse, quality of life assessment and stomach cramps. Higher score means worse outcome. The responses to the statements except for statement 7 (I am content with the quality of my life right now) were reversed and the sum of non-missing responses is calculated. The FOSI score is the sum multiplied by 8, then divided by the number of responded statements. The FOSI score was missing if a participants had 5 or more missing values in the 8 individual symptom scores at a visit.

Time frame:
Baseline and at Cycle 3 Day 1 (cycle length is 28 days).
Reported as:
Mean · score on a scale
Change From Baseline at Cycle 3 Day 1 Treatment in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score
score on a scaleNirogacestat Open-Label
Change From Baseline at Cycle 3 Day 1 Treatment in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score-1.2 ± 4.00
SecondaryChange From Baseline at Cycle 4 Day 1 in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score

Participant reported ovarian cancer symptoms as measured by Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI). The FOSI is an 8-question evaluation scored on a Likert scale of 0-4 from not at all to very much. Metrics assessed include lack of energy, vomiting, pain, nausea, swelling in stomach area, concern condition will get worse, quality of life assessment and stomach cramps. Higher score means worse outcome. The responses to the statements except for statement 7 (I am content with the quality of my life right now) were reversed and the sum of non-missing responses is calculated. The FOSI score is the sum multiplied by 8, then divided by the number of responded statements. The FOSI score was missing if a participants had 5 or more missing values in the 8 individual symptom scores at a visit.

Time frame:
Baseline and at Cycle 4 Day 1 (cycle length is 28 days).
Reported as:
Mean · score on a scale
Change From Baseline at Cycle 4 Day 1 in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score
score on a scaleNirogacestat Open-Label
Change From Baseline at Cycle 4 Day 1 in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score-1.5 ± 3.08
SecondaryChange From Baseline at Cycle 5 Day 1 in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score

Participant reported ovarian cancer symptoms as measured by Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI). The FOSI is an 8-question evaluation scored on a Likert scale of 0-4 from not at all to very much. Metrics assessed include lack of energy, vomiting, pain, nausea, swelling in stomach area, concern condition will get worse, quality of life assessment and stomach cramps. Higher score means worse outcome. The responses to the statements except for statement 7 (I am content with the quality of my life right now) were reversed and the sum of non-missing responses is calculated. The FOSI score is the sum multiplied by 8, then divided by the number of responded statements. The FOSI score was missing if a participants had 5 or more missing values in the 8 individual symptom scores at a visit.

Time frame:
Baseline and at Cycle 5 Day 1 (cycle length is 28 days).
Reported as:
Mean · score on a scale
Change From Baseline at Cycle 5 Day 1 in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score
score on a scaleNirogacestat Open-Label
Change From Baseline at Cycle 5 Day 1 in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score-1.3 ± 3.36
SecondaryChange From Baseline at End of Treatment in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score

Participant reported ovarian cancer symptoms as measured by Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI). The FOSI is an 8-question evaluation scored on a Likert scale of 0-4 from not at all to very much. Metrics assessed include lack of energy, vomiting, pain, nausea, swelling in stomach area, concern condition will get worse, quality of life assessment and stomach cramps. Higher score means worse outcome. The responses to the statements except for statement 7 (I am content with the quality of my life right now) were reversed and the sum of non-missing responses is calculated. The FOSI score is the sum multiplied by 8, then divided by the number of responded statements. The FOSI score was missing if a participants had 5 or more missing values in the 8 individual symptom scores at a visit.

Time frame:
Baseline and at end of treatment (estimated to be an average of 5.5 months [minimum of 0 month and maximum of 33 months]).
Reported as:
Mean · score on a scale
Change From Baseline at End of Treatment in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score
score on a scaleNirogacestat Open-Label
Change From Baseline at End of Treatment in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score-2.2 ± 4.48
SecondaryChange From Baseline at Safety Follow-up in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score

Participant reported ovarian cancer symptoms as measured by Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI). The FOSI is an 8-question evaluation scored on a Likert scale of 0-4 from not at all to very much. Metrics assessed include lack of energy, vomiting, pain, nausea, swelling in stomach area, concern condition will get worse, quality of life assessment and stomach cramps. Higher score means worse outcome. The responses to the statements except for statement 7 (I am content with the quality of my life right now) were reversed and the sum of non-missing responses is calculated. The FOSI score is the sum multiplied by 8, then divided by the number of responded statements. The FOSI score was missing if a participants had 5 or more missing values in the 8 individual symptom scores at a visit.

Time frame:
Baseline and at safety follow-up (up to a maximum of 34 months).
Reported as:
Mean · score on a scale
Change From Baseline at Safety Follow-up in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score
score on a scaleNirogacestat Open-Label
Change From Baseline at Safety Follow-up in the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI) Score-0.8 ± 3.75

Adverse events

Collected over All SAEs and AEs were collected from the time of signing ICF until 30 days after the last dose of study treatment (an average of 5.5 months [minimum of 0 month and maximum of 33 months] and up to 34 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nirogacestat Open-Label7/53 (13.2%)12/53 (22.6%)52/53 (98.1%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventNirogacestat Open-Label
Abdominal painGastrointestinal disorders4/53
Acute kidney injuryRenal and urinary disorders2/53
DehydrationMetabolism and nutrition disorders2/53
DiarrhoeaGastrointestinal disorders2/53
HypokalaemiaMetabolism and nutrition disorders2/53
Small intestinal obstructionGastrointestinal disorders2/53
Acute myocardial infarctionCardiac disorders1/53
Angina pectorisCardiac disorders1/53
Cardio-respiratory arrestCardiac disorders1/53
ColitisGastrointestinal disorders1/53
Most frequent other events
Showing 10 of 61
Most frequent other events
EventNirogacestat Open-Label
DiarrhoeaGastrointestinal disorders38/53
NauseaGastrointestinal disorders30/53
FatigueGeneral disorders21/53
VomitingGastrointestinal disorders20/53
CoughRespiratory, thoracic and mediastinal disorders17/53
Rash maculo-papularSkin and subcutaneous tissue disorders17/53
HypophosphataemiaMetabolism and nutrition disorders15/53
Abdominal painGastrointestinal disorders11/53
HypokalaemiaMetabolism and nutrition disorders10/53
EpistaxisRespiratory, thoracic and mediastinal disorders8/53

Baseline characteristics

Full Analysis Set which consisted of of all participants who received at least 1 dose of nirogacestat.

Age, Continuous
Age, Continuous(years)Nirogacestat Open-Label
Mean55.1 ± 12.85
Age, Customized
Age, Customized(Participants)Nirogacestat Open-Label
<45 years13
>=45 years40
Sex: Female, Male
Sex: Female, Male(Participants)Nirogacestat Open-Label
Female53
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nirogacestat Open-Label
Hispanic or Latino6
Not Hispanic or Latino43
Unknown or Not Reported4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nirogacestat Open-Label
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American4
White37
More than one race2
Unknown or Not Reported7
Region of Enrollment
Region of Enrollment(Participants)Nirogacestat Open-Label
United States50
Poland3
Baseline Weight
Baseline Weight(kilogram)Nirogacestat Open-Label
Mean82.48 ± 19.672
Baseline Height
Baseline Height(meter)Nirogacestat Open-Label
Mean1.632 ± 0.0611
08

Study locations

21 sites
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • UCLA-JCCC Dept. of OBGYN - Women's Health Clinical Research Unit
    Los Angeles, California 90095, United States
  • AdventHealth Orlando
    Orlando, Florida 32804, United States
  • Orlando Health Cancer Institute
    Orlando, Florida 32806, United States
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Women's Cancer Care
    Covington, Louisiana 70433, United States
  • Greater Baltimore Medical Center
    Baltimore, Maryland 21204, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • David C. Pratt Cancer Center
    St Louis, Missouri 63141, United States
  • University of New Mexico Comprehensive Cancer Center
    Albuquerque, New Mexico 87102, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Institute
    New York, New York 10065, United States
  • Women's Cancer Center at Kettering
    Kettering, Ohio 45429, United States
  • OU Health Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • UW/Fred Hutch Cancer Center
    Seattle, Washington 98109, United States
  • Froedtert and Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Maria Sklodowska-Curie Bialystok Oncology Center
    Bialystok, 15-027, Poland
  • Jagiellonian Innovation Centre Clinical Research Centre
    Krakow, 30-348, Poland
  • University Teaching Hospital Poznan, Department of Oncological Gynaecology
    Poznan, 60-569, Poland
  • Maria Sklodowska-Curie National Institute of Oncology-National Research Institute, Clinic of Oncological Gynecology
    Warsaw, 02-781, Poland
09

References and documents

Publications

  • Grisham RN, Hopp E, Pennington K, Holloway R, Wenham RM, Blecharz P, Dockery L, Matsuo K, Salani R, Bidzinski M, Braly P, Celano P, Reid T, Seward S, Lewis J, Johnson M, DuBose R, Ahn S, Cheng S, Alvero C, Konstantinopoulos PA. Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours. Clin Transl Med. 2026 Jan;16(1):e70568. doi: 10.1002/ctm2.70568. PubMed 41518037 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD supporting publicly available results will be evaluated for sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: IPD from completed trials will be publicly available within 6 months after all of the following events: Approval of a product/new indication by major authorities (FDA, EMA, PMDA if requested) with no pending submissions Public results via primary manuscript or trial registry disclosure Legal authority to share data Privacy protections are in place If approval is not sought or development is globally discontinued, data will be publicly available within 18 months after global trial completion. Further information on how to request data can be found on our website bit.ly/IPD21

Access criteria: Qualified researchers may propose access to IPD from sponsored trials via https://vivli.org/members/ourmembers/.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jul 2025, 34 months.

Results were first posted in Aug 2026, 1 year 1 month after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 34 months is close to that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2022
First posted
Apr 27, 2022
StartActual
Aug 30, 2022
Primary completionActual
Jul 8, 2025
CompletionActual
Jul 14, 2025
Results first posted
Aug 25, 2026
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05348356
Responsible party
Sponsor
First posted
Apr 27, 2022
Start date
Aug 30, 2022
Primary completion
Jul 8, 2025
Completion
Jul 14, 2025
Results posted
Aug 25, 2026
Last update
Aug 25, 2026

Study contacts

Medical Responsible
study director · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirogacestat

Start the discussion